PURPOSE: To assess the prognostic value of perineural invasion (PNI) for patients treated with dose-escalated external-beam radiation therapy for prostate cancer. METHODS AND MATERIALS: Outcomes were analyzed for 651 men treated for prostate cancer with EBRT to a minimum dose ≥75 Gy. We assessed the impact of PNI as well as pretreatment and treatment-related factors on freedom from biochemical failure (FFBF), freedom from metastasis (FFM), cause-specific survival (CSS), and overall survival. RESULTS: PNI was present in 34% of specimens at biopsy and was significantly associated with higher Gleason score (GS), T stage, and prostate-specific antigen level. On univariate and multivariate analysis, the presence of PNI was associated with worse FFBF (hazard ratio = 1.7, p <0.006), FFM (hazard ratio = 1.8, p <0.03), and CSS (HR = 1.4, p <0.05) compared with absence of PNI; there was no difference in overall survival. Seven-year rates of FFBF, FFM, and CCS were 64% vs. 80%, 84% vs. 92%, and 91% vs. 95% for those patients with and without PNI, respectively. On recursive partitioning analysis, PNI predicted for worse FFM and CSS in patients with GS 8-10, with FFM of 67% vs. 89% (p <0.02), and CSS of 69% vs. 91%, (p <0.04) at 7 years for those with and without PNI, respectively. CONCLUSIONS: The presence of PNI in the prostate biopsy predicts worse clinical outcome for patients treated with dose-escalated external-beam radiation therapy. Particularly in patients with GS 8-10 disease, the presence of PNI suggests an increased risk of metastasis and prostate cancer death.
PURPOSE: To assess the prognostic value of perineural invasion (PNI) for patients treated with dose-escalated external-beam radiation therapy for prostate cancer. METHODS AND MATERIALS: Outcomes were analyzed for 651 men treated for prostate cancer with EBRT to a minimum dose ≥75 Gy. We assessed the impact of PNI as well as pretreatment and treatment-related factors on freedom from biochemical failure (FFBF), freedom from metastasis (FFM), cause-specific survival (CSS), and overall survival. RESULTS: PNI was present in 34% of specimens at biopsy and was significantly associated with higher Gleason score (GS), T stage, and prostate-specific antigen level. On univariate and multivariate analysis, the presence of PNI was associated with worse FFBF (hazard ratio = 1.7, p <0.006), FFM (hazard ratio = 1.8, p <0.03), and CSS (HR = 1.4, p <0.05) compared with absence of PNI; there was no difference in overall survival. Seven-year rates of FFBF, FFM, and CCS were 64% vs. 80%, 84% vs. 92%, and 91% vs. 95% for those patients with and without PNI, respectively. On recursive partitioning analysis, PNI predicted for worse FFM and CSS in patients with GS 8-10, with FFM of 67% vs. 89% (p <0.02), and CSS of 69% vs. 91%, (p <0.04) at 7 years for those with and without PNI, respectively. CONCLUSIONS: The presence of PNI in the prostate biopsy predicts worse clinical outcome for patients treated with dose-escalated external-beam radiation therapy. Particularly in patients with GS 8-10 disease, the presence of PNI suggests an increased risk of metastasis and prostate cancer death.
Authors: F O'Kelly; S Elamin; A Cahill; P Aherne; J White; J Buckley; K N O'Regan; A Brady; D G Power; M F O'Brien; P Sweeney; N Mayer; P J Kelly Journal: World J Urol Date: 2013-10-16 Impact factor: 4.226
Authors: Piotr Zareba; Richard Flavin; Masis Isikbay; Jennifer R Rider; Travis A Gerke; Stephen Finn; Andreas Pettersson; Francesca Giunchi; Robert H Unger; Alex M Tinianow; Swen-Olof Andersson; Ove Andrén; Katja Fall; Michelangelo Fiorentino; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-01-06 Impact factor: 4.254
Authors: Shizhi He; Shuangba He; Chun-Hao Chen; Sylvie Deborde; Richard L Bakst; Natalya Chernichenko; William F McNamara; Sei Young Lee; Fernando Barajas; Zhenkun Yu; Hikmat A Al-Ahmadie; Richard J Wong Journal: Mol Cancer Res Date: 2014-10-13 Impact factor: 5.852
Authors: Emily R Holthoff; Susanne K Jeffus; Ashita Gehlot; Rebecca Stone; Stephen W Erickson; Thomas Kelly; Charles M Quick; Steven R Post Journal: Am J Surg Pathol Date: 2015-08 Impact factor: 6.394
Authors: Michael A Liss; Adam Gordon; Blanca Morales; Kathryn Osann; Douglas Skarecky; Achim Lusch; Frank Zaldivar; Thomas E Ahlering Journal: Urol Oncol Date: 2014-04-29 Impact factor: 3.498
Authors: Robert M Turner; Todd S Yecies; Jonathan G Yabes; Benjamin T Ristau; Elen Woldemichael; Benjamin J Davies; Bruce L Jacobs; Joel B Nelson Journal: Urology Date: 2016-11-15 Impact factor: 2.649